Feds Finally Downgrade Medical Pot from 'Heroin-Level' Ban
Published Date: 4/28/2026
Rule
Summary
Starting April 28, 2026, FDA-approved marijuana-based medicines move from the strictest drug category (Schedule I) to a less strict one (Schedule III). This change helps medical marijuana businesses get faster federal permits to make and sell these products legally. Patients and companies benefit from easier access and clearer rules, while the government keeps control to meet international drug laws.
Analyzed Economic Effects
8 provisions identified: 3 benefits, 3 costs, 2 mixed.
State Licensees No Longer Subject to Section 280E
The rule states that, as a consequence, state medical marijuana licensees will no longer be subject to the deduction disallowance in Section 280E of the Internal Revenue Code, which applies only to businesses trafficking in Schedule I or II substances. The rule notes licensees should consult tax counsel about their specific tax liability.
FDA-Approved Marijuana Moved to Schedule III
Starting April 28, 2026, FDA-approved drug products that contain marijuana and marijuana covered by state medical marijuana licenses are placed in Schedule III of the Controlled Substances Act. This changes federal classification for those FDA-approved medical marijuana products and state-licensed medical marijuana.
Expedited DEA Registration For State Licensees
The rule creates an expedited DEA registration pathway for entities holding state medical marijuana licenses and directs that applications submitted within 60 days of publication must be processed within six months; early applicants may lawfully operate under their state license while DEA reviews their application. A DEA registration will automatically suspend if the underlying state license is suspended, revoked, or expires.
DEA Registration Rules, Fees, and Operational Requirements
Persons handling FDA-approved marijuana products must obtain DEA registration as Schedule III handlers and comply with Schedule III rules (records, security, labeling, disposal, inventory). The rule lists current registration fees: Manufacturers $3,699 annually; Distributors $1,850 annually; Dispensers (including pharmacies) $888 for a registration valid for 3 years. Registrants must inventory controlled substances every two years.
Unlicensed Bulk Marijuana, Quotas, and DEA Purchase Duty Stay in Schedule I
Unlicensed bulk marijuana, marijuana extracts, and Delta-9-THC material not in FDA-approved products remain Schedule I and remain subject to quota provisions and DEA obligations (including DEA purchase and monopoly of wholesale trade for such crops). State-licensed marijuana remains subject to treaty-related quota requirements but is exempted from wholesale monopoly when it qualifies as 'medicinal cannabis.'
Import/Export Permit Requirement Preserved
DEA amends regulations to require that all importations and exportations of FDA-approved drug products containing marijuana and state-licensed medical marijuana remain subject to an import/export permit. The import/export permit requirement continues to apply even after rescheduling.
Prescriptions Required For Dispensing
Prescriptions are required prior to dispensing FDA-approved drug products containing marijuana except when dispensed directly by a DEA-registered practitioner (e.g., physician, hospital). Prescriptions must include drug name, strength, dosage form, quantity prescribed, and directions for use.
Synthetic THC and Hemp Status Unchanged
The rule explicitly leaves synthetically derived THC (e.g., delta-10-THC) in Schedule I and does not change the status of hemp as defined in 7 U.S.C. 1639o. The rescheduling applies only to marijuana as defined in the CSA when in FDA-approved products or subject to state medical marijuana licenses.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical often linked to illegal drug use—into Schedule I, the strictest drug category. This means anyone making, selling, or using it faces serious legal rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without adding new costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the Schedule I drug list starting May 4, 2026. This means HHC, a synthetic cousin of THC, is clearly controlled as a hallucinogen with a unique code, making rules easier to follow. Anyone making, selling, or using HHC should know it’s officially regulated now, but no new fees or costs are added.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but the registration could speed up important drug studies.
2026-08517 — Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
Starting May 1, 2026, the DEA officially puts four tricky chemicals—4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA—into Schedule I, meaning they’re now illegal to make, sell, or use without special permission. This affects anyone handling these substances, who will face strict rules and possible penalties. The move helps keep dangerous synthetic drugs off the streets and protects public health.
2026-08177 — Schedules of Controlled Substances: Rescheduling of Marijuana
The DEA is planning to move marijuana to Schedule III, which means it’s seen as less risky and easier to access legally. This change affects anyone using, selling, or researching marijuana and kicks off with a public hearing starting June 29, 2026. If you want to join the conversation, you need to sign up by May 28, 2026, so get ready for some big shifts in marijuana rules and opportunities!
2026-08104 — Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
Starting April 27, 2026, the DEA is officially putting MDMB-4en-PINACA—a powerful and risky chemical—into Schedule I, the strictest drug category. This means anyone making, selling, or using it will face serious legal rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer from this dangerous substance.
Previous / Next Documents
Previous: 2026-08172 — Magnuson-Stevens Act Provisions; Fisheries of the Northeastern United States; Northeast Multispecies Fishery; Allocation of 2026 Northeast Multispecies Annual Catch Entitlements and Notice of Default Specifications
The 2026 fishing season for Northeast multispecies groundfish is set! Approved fishing groups get their catch limits starting May 1, 2026, so they can keep fishing without a hitch. If new rules don’t come by October 31, some fishing spots will close starting November 1, 2026, to protect fish stocks and keep things fair.
Next: 2026-08191 — Amendment of Class E Airspace; Miami, FL
The FAA fixed some airport name mistakes in the Miami airspace rules that were published earlier this year. This update doesn’t change when the rules start—July 9, 2026—but makes sure pilots and controllers have the right info. If you fly or work near Miami airports, these corrections keep everything clear and safe without costing extra money.